The purpose of this study is to understand how your gut plays a role in how well CAR T cell therapy works. Your gut is home to bacteria, which we call the gut microbiome. The gut microbiome can send signals to your immune cells, which may impact how well and how long CAR T cell therapy will last. We can find out what type of bacteria are in your gut microbiome by studying your stool. We can understand more about the signals sent to the immune system by studying your blood. We will ask for stool and blood at the same time points throughout your treatment. We will study the identities and function of the bacteria and immune cells to understand more about how these signals work during CAR T cell treatment.

This study wants to learn how people with cancer manage their day-to-day health and treatment while receiving medicines for cancer. We will ask patients about their experiences through short surveys and interviews to understand what helps them stay well and avoid emergency visits or hospital stays. The goal is to find ways to better support patients during treatment, especially those who live farther from the hospital or have fewer resources.

The purpose of this study is to develop a prospective longitudinal cohort/registry of lymphoma patients in Malawi to address a lack of prospective longitudinal data related to lymphoma in sub-Saharan Africa, and to serve as a foundation for developing optimal treatment strategies in this challenging environment.

We are collecting blood and optionally stool, bone marrow or tissue samples from patients who received cell therapy or a stem cell transplant to treat cancer. This will help understand how the immune system recovers after cell therapy or stem cell transplant and how it may relate to patient outcomes.

To create digital tools to support young adult cancer survivors completing active treatment and transitioning into survivorship care.

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

The goal of the study is to determine why some men and women get certain types of head and neck (mouth or throat) cancer, and others do not. If we can identify underlying causes of head and neck cancer, we can determine ways to prevent it from occurring. Collection and analysis of medical records and tumor biology may also lead to more effective treatments and lower the death rate from this disease.

This phase 3 trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will

To assess the safety of nonconforming lisocabtagene maraleucel in patients

This study aims to design and improve tools that can be used to select strategies for improving colorectal cancer screening in different settings and populations. Interviews, surveys, and focus groups will be conducted with individuals who make decisions related to colorectal cancer screening interventions about their understanding, preferences, and suggestions related to these tools and intervention strategies.